Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

Further to Decision 46 COM 9A, this document presents a report on the implementation of the Upstream Process requests since the 46th session of the World Heritage Committee (New Delhi, 2024). It also ...

Bioprocessing comprises the integrated design, optimisation and control of biological systems used to produce commercially valuable products. It harnesses living cells, enzymes or whole organisms, ...

Polyethylenimine (PEI)-assisted transfection is a mainstay in upstream processing (USP) for viral vector manufacturing. But recent developments are shifting it from a ...